Healthy food prescription incentive programme for adults with type 2 diabetes who are experiencing food insecurity: protocol for a randomised controlled trial, modelling and implementation studies
Author:
Olstad Dana LeeORCID, Beall Reed, Spackman Eldon, Dunn Sharlette, Lipscombe Lorraine L, Williams Kienan, Oster Richard, Scott Sara, Zimmermann Gabrielle L, McBrien Kerry A, Steer Kieran J D, Chan Catherine B, Tyminski Sheila, Berkowitz SethORCID, Edwards Alun L, Saunders-Smith Terry, Tariq Saania, Popeski Naomi, White Laura, Williamson Tyler, L'Abbé Mary, Raine Kim D, Nejatinamini Sara, Naser Aruba, Basualdo-Hammond Carlota, Norris Colleen, O’Connell Petra, Seidel Judy, Lewanczuk Richard, Cabaj Jason, Campbell David J TORCID
Abstract
IntroductionThe high cost of many healthy foods poses a challenge to maintaining optimal blood glucose levels for adults with type 2 diabetes mellitus who are experiencing food insecurity, leading to diabetes complications and excess acute care usage and costs. Healthy food prescription programmes may reduce food insecurity and support patients to improve their diet quality, prevent diabetes complications and avoid acute care use. We will use a type 2 hybrid-effectiveness design to examine the reach, effectiveness, adoption, implementation and maintenance (RE-AIM) of a healthy food prescription incentive programme for adults experiencing food insecurity and persistent hyperglycaemia. A randomised controlled trial (RCT) will investigate programme effectiveness via impact on glycosylated haemoglobin (primary outcome), food insecurity, diet quality and other clinical and patient-reported outcomes. A modelling study will estimate longer-term programme effectiveness in reducing diabetes-related complications, resource use and costs. An implementation study will examine all RE-AIM domains to understand determinants of effective implementation and reasons behind programme successes and failures.Methods and analysis594 adults who are experiencing food insecurity and persistent hyperglycaemia will be randomised to a healthy food prescription incentive (n=297) or a healthy food prescription comparison group (n=297). Both groups will receive a healthy food prescription. The incentive group will additionally receive a weekly incentive (CDN$10.50/household member) to purchase healthy foods in supermarkets for 6 months. Outcomes will be assessed at baseline and follow-up (6 months) in the RCT and analysed using mixed-effects regression. Longer-term outcomes will be modelled using the UK Prospective Diabetes Study outcomes simulation model-2. Implementation processes and outcomes will be continuously measured via quantitative and qualitative data.Ethics and disseminationEthical approval was obtained from the University of Calgary and the University of Alberta. Findings will be disseminated through reports, lay summaries, policy briefs, academic publications and conference presentations.Trial registration numberNCT04725630.Protocol versionVersion 1.1; February 2022
Funder
Alberta Health Services Alberta Innovates Alberta Blue Cross Nu Skin Canadian Institutes of Health Research
Reference175 articles.
1. Economic Costs of Diabetes in the U.S. in 2017 2. Health care system cost of people with diabetes, 2013. Available: https://open.alberta.ca/dataset/a2a60d91-081e-42c8-8d4a-466bb3506399/resource/34c90d83-caa3-4def-ab78-3a8987e2d7d7/download/phsb-03-2013-diabetes-cost.pdf 3. New diabetes rates released with urgent plea for governments to implement national diabetes strategy, 2019. Available: https://www.diabetes.ca/media-room/press-releases/new-diabetes-rates-released-with-urgent-plea-for-governments-to-implement-national-diabetes-strategy#:~:text=Jan%20Hux%2C%20President%20and%20CEO,under%20%2430%20billion%20this%20year 4. Quantitative Economic Decisions Inc: Canadian Diabetes Cost Model. The Canadian Diabetes Cost Model was developed for diabetes Canada by quantitative economic decisions, Inc. (formerly Informetrica Limited) and publicly released in 2009. The forecasting model provides projections about the prevalence, incidence and economic burden of diabetes for Canadian society based on national surveillance data from the Canadian chronic disease surveillance system 2009. 5. Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|